< div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " > INDIANAPOLIS and KENILWORTH, N.J. < /div > < /div > < /div > < p > INDIANAPOLIS and KENILWORTH, N.J. – Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MR..."> < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " > INDIANAPOLIS and KENILWORTH, N.J. < /div > < /div > < /div > < p > INDIANAPOLIS and KENILWORTH, N.J. – Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MR..." /> < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " > INDIANAPOLIS and KENILWORTH, N.J. < /div > < /div > < /div > < p > INDIANAPOLIS and KENILWORTH, N.J. – Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MR..." />

Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA ® (pembrolizumab) Combination Trial

< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " > INDIANAPOLIS and KENILWORTH, N.J. < /div > < /div > < /div > < p > INDIANAPOLIS and KENILWORTH, N.J. – Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly’s cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck’s KEYTRUDA® (pembr olizumab) in a Phase I study across multiple tumor types. < /p > < div class= " field field-type-text field-field-press-release-language field-fieldpressreleaselanguage " > < div class= " field-label " > Language: < /div > < div class= " field-items " > < div class= " field-item odd " > English < /div > < /div > < /div > < p > < a href= " http://www.mercknewsroom.com/news-release/prescription-medicine-news/lilly-and-merck-expand-immuno-oncology-collaboration-adding- " target= " _blank " > read more < /a > < /p >
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news